
Allogene launches first allogeneic CAR-T phase II trial
On October 6, Allogene announced the initiation of the Phase II ALPHA2 trial of the investigational allogeneic CAR T therapy ALLO-501A for the treatment of
On October 6, Allogene announced the initiation of the Phase II ALPHA2 trial of the investigational allogeneic CAR T therapy ALLO-501A for the treatment of